(Q36491803)

14 August 2017

1 reference

title

Treatment of interferon-alpha for chronic hepatitis C. (English)

1 reference

14 August 2017

1 reference

Mitsuhiko Moriyama

1

1 reference

14 August 2017

Yasuyuki Arakawa

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

9

1 reference

14 August 2017

page(s)

1163-1179

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Weight-based dosing: which impact on efficacy and safety of therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

HCV chronic hepatitis in patients with HIV: clinical management issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Treatment of hepatitis C virus infection in thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Pilot study of prolonged interferon-alpha retreatment in chronic hepatitis C patients with genotype 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Treatment of hepatitis C in the patient with decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Treatment of hepatitis C: critical appraisal of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Clinical outcome of hepatitis C as a function of mode of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

A randomized clinical trial with natural interferon-alpha monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.9.1163

10.1517/14656566.7.9.1163

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference